LT3377516T - Kompozicija vėžiui gydyti - Google Patents

Kompozicija vėžiui gydyti

Info

Publication number: LT3377516T
Authority: LT; Lithuania
Prior art keywords: composition; treating cancer; cancer; treating
Prior art date: 2015-11-20

Application number

LTEPPCT/US2016/062865T

Other languages

English (en)

Inventor

David A. Scheinberg

Original Assignee

Memorial Sloan Kettering Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-20

Filing date

2016-11-18

Publication date

2022-09-26

2016-11-18 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center

2022-09-26 Publication of LT3377516T publication Critical patent/LT3377516T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001141—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Virology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LTEPPCT/US2016/062865T 2015-11-20 2016-11-18 Kompozicija vėžiui gydyti LT3377516T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562258134P	2015-11-20	2015-11-20
PCT/US2016/062865 WO2017087857A1 (en)	2015-11-20	2016-11-18	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
LT3377516T true LT3377516T (lt)	2022-09-26

Family

ID=58717878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2016/062865T LT3377516T (lt)	2015-11-20	2016-11-18	Kompozicija vėžiui gydyti

Country Status (21)

Country	Link
US (1)	US11033613B2 (lt)
EP (2)	EP4130026A1 (lt)
JP (4)	JP6991969B2 (lt)
KR (2)	KR20250099263A (lt)
CN (4)	CN116327903A (lt)
AU (2)	AU2016356708B2 (lt)
CA (2)	CA3255544A1 (lt)
CY (1)	CY1125628T1 (lt)
DK (1)	DK3377516T3 (lt)
ES (1)	ES2926386T3 (lt)
HR (1)	HRP20220994T1 (lt)
HU (1)	HUE059694T2 (lt)
LT (1)	LT3377516T (lt)
MA (1)	MA43283B1 (lt)
MD (1)	MD3377516T2 (lt)
PL (1)	PL3377516T3 (lt)
PT (1)	PT3377516T (lt)
RS (1)	RS63561B1 (lt)
SI (1)	SI3377516T1 (lt)
SM (1)	SMT202200370T1 (lt)
WO (1)	WO2017087857A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2010209B1 (en) *	2006-04-10	2016-06-15	Sloan Kettering Institute For Cancer Research	Immunogenic wt-1 peptides and methods of use thereof
WO2015109391A1 (en)	2014-01-24	2015-07-30	Children's Hospital Of Eastern Ontario Research Institute Inc.	Smc combination therapy for the treatment of cancer
HUE059694T2 (hu)	2015-11-20	2022-12-28	Memorial Sloan Kettering Cancer Center	Készítmény rák kezelésére
SG11201808552XA (en)	2016-05-18	2018-10-30	Cue Biopharma Inc	T-cell modulatory multimeric polypeptides and methods of use thereof
CN109715196A (zh)	2016-06-13	2019-05-03	转矩医疗股份有限公司	用于促进免疫细胞功能的组合物和方法
KR20190082850A (ko)	2016-11-30	2019-07-10	어드박시스, 인크.	반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
CN110325205B (zh)	2016-12-22	2023-08-15	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en)	2017-01-09	2023-12-26	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko)	2017-03-15	2024-01-12	큐 바이오파마, 인크.	면역 반응을 조절하는 방법
WO2019006401A2 (en) *	2017-06-30	2019-01-03	Advaxis, Inc.	LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
CA3074826A1 (en)	2017-09-05	2019-03-14	Torque Therapeutics, Inc.	Therapeutic protein compositions and methods of making and using the same
US20210177955A1 (en) *	2017-11-08	2021-06-17	Advaxis, Inc.	Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
WO2019139896A1 (en)	2018-01-09	2019-07-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019173499A1 (en) *	2018-03-06	2019-09-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	17-beta-hydroxywithanolides and use thereof in treating cancer
US12440546B2 (en) *	2018-10-05	2025-10-14	International Institute Of Cancer Immunology, Inc.	Composition for preventing or treating benign tumor
TWI856047B (zh)	2018-12-19	2024-09-21	美商信號生物製藥公司	多聚體ｔ細胞調節多肽及其使用方法
CN114072171A (zh) *	2019-04-10	2022-02-18	Slsg有限责任公司	多价免疫治疗组合物和用于治疗wt1阳性癌症的方法
US20220396839A1 (en)	2019-11-12	2022-12-15	Foundation Medicine, Inc.	Methods of detecting a fusion gene encoding a neoantigen
KR102764120B1 (ko)	2019-12-31	2025-02-06	엘릭서젠 쎄라퓨틱스, 인크.	핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
EP4132490A4 (en) *	2020-04-07	2024-04-24	Metanoi Therapeutics, Inc.	ETHANOLAMINE FORMULATION FOR THE TREATMENT OF EPITHELIAL OVARIAN CARCINOMA
IL296209A (en)	2020-05-12	2022-11-01	Cue Biopharma Inc	Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja)	2020-09-09	2023-10-02	キューバイオファーマ，インコーポレイテッド	１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
EP0573608A1 (en)	1991-02-07	1993-12-15	Molecumetics, Ltd.	Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2168245A1 (en)	1993-07-29	1995-02-09	C. Anthony Hunt	Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
US5643786A (en)	1995-01-27	1997-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Method for isolating dendritic cells
AU4932199A (en)	1998-07-31	2000-02-21	Haruo Sugiyama	Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
KR100752065B1 (ko) *	1998-09-30	2007-08-28	코릭사 코포레이션	Ｗｔ1 특이적 면역요법용 조성물 및 방법
US7655249B2 (en)	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en)	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
US7329410B1 (en)	1998-09-30	2008-02-12	Corixa Corporation	Compositions and method for WT1 specific immunotherapy
US7901693B2 (en)	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en)	1998-09-30	2006-10-03	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en)	2000-10-09	2006-12-05	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (en)	1999-10-04	2001-04-12	Corixa Corporation	Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en)	2000-02-22	2003-05-01	Alexander Gaiger	Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en)	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
WO2003106682A1 (ja)	2002-06-12	2003-12-24	中外製薬株式会社	Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2478446T3 (es)	2003-06-27	2014-07-22	International Institute Of Cancer Immunology, Inc.	Método de selección de pacientes candidatos para la vacuna contra WT1
WO2005045027A1 (ja)	2003-11-05	2005-05-19	International Institute Of Cancer Immunology, Inc.	Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
ES2402184T5 (es)	2003-12-01	2016-10-25	Sloan-Kettering Institute For Cancer Research	Análogos de péptidos de unión a HLA sintéticos y sus usos
US20060127409A1 (en)	2003-12-01	2006-06-15	Scheinberg David A	Bcr-abl vaccines and methods of use thereof
EP2565201B1 (en) *	2005-10-17	2014-11-26	Sloan-Kettering Institute For Cancer Research	WT1 HLA class II-binding peptides and compositions and methods comprising same
DE102006014261A1 (de)	2006-03-28	2007-10-04	Dr.Ing.H.C. F. Porsche Ag	Luftleitvorrichtung für ein Fahrzeug
EP2010209B1 (en)	2006-04-10	2016-06-15	Sloan Kettering Institute For Cancer Research	Immunogenic wt-1 peptides and methods of use thereof
WO2009072610A1 (ja)	2007-12-05	2009-06-11	International Institute Of Cancer Immunology, Inc.	癌ワクチン組成物
US20110136141A1 (en)	2009-12-03	2011-06-09	Abbott Laboratories	Peptide reagents and method for inhibiting autoantibody antigen binding
EP3520810A3 (en) *	2012-01-13	2019-11-06	Memorial Sloan-Kettering Cancer Center	Immunogenic wt1 peptides and use thereof
LT2945647T (lt)	2013-01-15	2021-02-25	Memorial Sloan Kettering Cancer Center	Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
CN103961702B (zh) *	2013-02-05	2019-04-09	日东电工株式会社	粘膜给予用wt1肽癌症疫苗组合物
MX428954B (es) *	2013-03-15	2025-11-13	Univ Pennsylvania	Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
WO2015061752A1 (en)	2013-10-25	2015-04-30	Pharmacyclics, Inc.	Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EA201690912A1 (ru)	2013-11-05	2016-10-31	Когнейт Биосервисис, Инк.	Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2015103602A1 (en)	2014-01-06	2015-07-09	The Trustees Of The University Of Pennsylvania	Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3119893A1 (en)	2014-03-17	2017-01-25	Taplmmune Inc.	Nucleic acid molecule vaccine compositions and uses thereof
ES2993462T3 (en) *	2015-05-20	2024-12-30	Sumitomo Pharma Co Ltd	Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
HUE059694T2 (hu)	2015-11-20	2022-12-28	Memorial Sloan Kettering Cancer Center	Készítmény rák kezelésére

2016
- 2016-11-18 HU HUE16867262A patent/HUE059694T2/hu unknown
- 2016-11-18 JP JP2018526090A patent/JP6991969B2/ja active Active
- 2016-11-18 ES ES16867262T patent/ES2926386T3/es active Active
- 2016-11-18 CA CA3255544A patent/CA3255544A1/en active Pending
- 2016-11-18 CN CN202210863762.9A patent/CN116327903A/zh active Pending
- 2016-11-18 CN CN201680077975.1A patent/CN108431022B/zh active Active
- 2016-11-18 AU AU2016356708A patent/AU2016356708B2/en active Active
- 2016-11-18 PL PL16867262.4T patent/PL3377516T3/pl unknown
- 2016-11-18 EP EP22175680.2A patent/EP4130026A1/en active Pending
- 2016-11-18 CN CN202210862167.3A patent/CN116327902A/zh active Pending
- 2016-11-18 US US15/777,514 patent/US11033613B2/en active Active
- 2016-11-18 SM SM20220370T patent/SMT202200370T1/it unknown
- 2016-11-18 LT LTEPPCT/US2016/062865T patent/LT3377516T/lt unknown
- 2016-11-18 DK DK16867262.4T patent/DK3377516T3/da active
- 2016-11-18 WO PCT/US2016/062865 patent/WO2017087857A1/en not_active Ceased
- 2016-11-18 KR KR1020257020131A patent/KR20250099263A/ko active Pending
- 2016-11-18 CN CN202210863749.3A patent/CN115920017A/zh active Pending
- 2016-11-18 KR KR1020187017393A patent/KR102823333B1/ko active Active
- 2016-11-18 RS RS20220828A patent/RS63561B1/sr unknown
- 2016-11-18 MD MDE20180934T patent/MD3377516T2/ro unknown
- 2016-11-18 CA CA3005896A patent/CA3005896C/en active Active
- 2016-11-18 SI SI201631597T patent/SI3377516T1/sl unknown
- 2016-11-18 PT PT168672624T patent/PT3377516T/pt unknown
- 2016-11-18 HR HRP20220994TT patent/HRP20220994T1/hr unknown
- 2016-11-18 EP EP16867262.4A patent/EP3377516B1/en active Active
- 2016-11-18 MA MA43283A patent/MA43283B1/fr unknown
2021
- 2021-12-08 JP JP2021198966A patent/JP2022033926A/ja active Pending
2022
- 2022-05-03 AU AU2022202973A patent/AU2022202973B2/en active Active
- 2022-09-13 CY CY20221100608T patent/CY1125628T1/el unknown
2023
- 2023-12-27 JP JP2023220529A patent/JP2024041809A/ja active Pending
2025
- 2025-12-19 JP JP2025269787A patent/JP2026053495A/ja active Pending

Also Published As

Publication number	Publication date
DK3377516T3 (da)	2022-09-19
JP2026053495A (ja)	2026-03-25
KR20180094922A (ko)	2018-08-24
JP2022033926A (ja)	2022-03-02
SI3377516T1 (sl)	2023-01-31
AU2022202973A1 (en)	2022-05-26
PT3377516T (pt)	2022-09-23
KR20250099263A (ko)	2025-07-01
EP3377516A1 (en)	2018-09-26
JP2024041809A (ja)	2024-03-27
CA3255544A1 (en)	2026-03-02
CN108431022A (zh)	2018-08-21
KR102823333B1 (ko)	2025-06-23
RS63561B1 (sr)	2022-10-31
EP3377516A4 (en)	2019-06-26
US20180339030A1 (en)	2018-11-29
PL3377516T3 (pl)	2022-10-10
EP4130026A1 (en)	2023-02-08
CA3005896C (en)	2025-09-23
SMT202200370T1 (it)	2022-11-18
US11033613B2 (en)	2021-06-15
AU2016356708A1 (en)	2018-07-05
WO2017087857A1 (en)	2017-05-26
CA3005896A1 (en)	2017-05-26
AU2022202973B2 (en)	2025-07-24
HRP20220994T1 (hr)	2022-11-11
JP6991969B2 (ja)	2022-03-03
MA43283B1 (fr)	2022-08-31
MA43283A (fr)	2018-09-26
CN116327902A (zh)	2023-06-27
EP3377516B1 (en)	2022-06-15
CN108431022B (zh)	2022-08-09
CN115920017A (zh)	2023-04-07
JP2018538265A (ja)	2018-12-27
CN116327903A (zh)	2023-06-27
ES2926386T3 (es)	2022-10-25
MD3377516T2 (ro)	2022-10-31
HUE059694T2 (hu)	2022-12-28
CY1125628T1 (el)	2026-02-25
AU2016356708B2 (en)	2022-02-03

Publication	Publication Date	Title
IL304820A (en)	2023-09-01	Preparations and methods for the treatment of cancer
SI3377516T1 (sl)	2023-01-31	Sestavek za zdravljenje raka
IL276545B (en)	2022-02-01	A method for treating cancer
ZA201706616B (en)	2021-03-31	Method for treating cancer
SG11201708861VA (en)	2017-11-29	Methods for treating cancer
SG11201705093UA (en)	2017-07-28	Composition for treating il-6-related diseases
IL246680A0 (en)	2016-08-31	Materials and preparations for the treatment of her2-positive tumors
IL255060A0 (en)	2017-12-31	Combined treatment for cancer
IL257691A (en)	2018-04-30	A method for treating cancer
IL256836B (en)	2021-04-29	Methods for treating cancer using apilimod
IL256523A (en)	2018-02-28	Compositions and methods for treating cancer
IL249231A0 (en)	2017-02-28	Pharmaceutical combinations for cancer treatment
PT3200815T (pt)	2021-05-07	Métodos e composições para o tratamento de cancro
IL259996A (en)	2018-07-31	Combinations for cancer treatment
SG11201610551TA (en)	2017-01-27	Combinations for treating cancers
IL255022A0 (en)	2017-12-31	Cancer treatment methods
IL255638A (en)	2018-01-31	Compositions and methods for treating cancer
SG11201605070UA (en)	2016-07-28	Novel methods for treating cancer
SG10202013112YA (en)	2021-02-25	Zinc-gamma-pga compositions and methods for treating cancer
ZA201707024B (en)	2019-02-27	Cancer treatment composition
IL255018A0 (en)	2017-12-31	Cancer treatment methods
PL3236961T3 (pl)	2020-11-30	Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
SG10201508795XA (en)	2017-05-30	Method for treating cancer
IL255016A0 (en)	2017-12-31	Cancer treatment methods
SG11201802292UA (en)	2018-04-27	Composition for treating pain